"L'IUCT Oncopole est composé de l'Institut Claudius Regaud, centre de lutte contre le cancer et de plusieurs équipes du CHU de Toulouse. Sur un même site, les deux établissements réunissent l'expertise de 1500 professionnels spécialisés en cancérologie. L'Institut est situé au cœur d'un campus regroupant des acteurs privés et publics investis dans la lutte contre le cancer. Trois missions lui sont confiées : le soin, la recherche et l'enseignement."

During the past decade, IUCT Oncopole; Hematologie conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 1 clinical trials were completed, i.e. on average, 6.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 1 clinical trials were completed. i.e. 9.1% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "IUCT Oncopole; Hematologie" #1 collaborator was "Acute Leukemia French Association" with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Janssen-Cilag Ltd." with 2 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "IUCT Oncopole; Hematologie" are "Acute Myeloid Leukemia" (4 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Acute Myeloblastic Leukemia" (1 trials), "Bruton Tyrosine Kinase Inhibitor" (1 trials) and "CLL, Refractory" (1 trials). Many other conditions were trialed in "IUCT Oncopole; Hematologie" in a lesser frequency.

Most popular intervention types in "IUCT Oncopole; Hematologie" are "Drug" (12 trials), "Behavioral" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "ACA Continuation" (1 trials), "Blinatumomab" (1 trials), "CPX-351" (1 trials) and "Cytarabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "IUCT Oncopole; Hematologie" are 15 trials for "All" genders.

Currently, there are NaN active trials in "IUCT Oncopole; Hematologie". undefined are not yet recruiting, 8 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in IUCT Oncopole; Hematologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in IUCT Oncopole; Hematologie, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".